The abstract is read at the publisher; the summary is JClub's.
Arlocabtagene autoleucel (arlo-cel) in heavily pretreated relapsed/refractory multiple myeloma produced an overall response rate of 87% with a median PFS of 18.3 months.
- Why it matters: Patients with RRMM after multiple prior therapies have limited options, and new targeted treatments are needed that balance efficacy with manageable toxicity.
- What they did: In a phase 1 dose-escalation/expansion study (N = 84), adult patients received a single IV infusion of 25 to 450 × 106 CAR T cells targeting GPRC5D, with safety and MTD as primary end points.
- The result: CRS occurred in 82% of patients and was mostly grade 1/2, with one CRS-related death at the highest dose; MTD was not reached, and 1-year OS was 90%.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.